Role of the VEGF/VEGFR pathways in the development, progression, and treatment of cholangiocellular carcinoma
10.3969/j.issn.1001-5256.2020.08.041
- VernacularTitle:血管内皮生长因子/血管内皮生长因子受体通路在胆管细胞癌发生发展及治疗中的作用
- Author:
Lun BO
1
;
Qiong ZHANG
1
;
Xiangxu WANG
1
;
Wei PAN
1
;
Hongmei ZHANG
1
Author Information
1. Department of Clinical Oncology, Xijing Hospital, Air Force Medical University, Xi’an 710032, China
- Publication Type:Research Article
- Keywords:
cholangiocarcinoma;
vascular endothelial growth factors;
angiogenesis inhibitors;
therapeutics
- From:
Journal of Clinical Hepatology
2020;36(8):1866-1869
- CountryChina
- Language:Chinese
-
Abstract:
Cholangiocellular carcinoma (CCA) is a malignant tumor derived from the biliary epithelium, with a lack of effective therapeutic drugs and poor prognosis. Studies have shown that the development and progression of CCA are closely associated with angiogenesis, and a variety of angiogenic factors, including vascular endothelial growth factor (VEGF) and its receptor VEGFR, can regulate angiogenesis in CCA, participate in the development and progression of CCA, and affect its prognosis. Therefore, anti-angiogenic drugs targeting VEGF/VEGFR, such as monoclonal antibodies and small-molecule inhibitors, have gradually become research hotspots for the treatment of CCA. This article reviews the role of the VEGF/VEGFR pathways in the clinical features and prognosis of CCA, the advances in anti-angiogenic therapy for CCA, and related studies on drug resistance.
